These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 22595021

  • 1. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
    Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, Barrett DA, Kendall DA, Bennett AJ, Chapman V.
    Br J Pharmacol; 2012 Oct; 167(3):627-40. PubMed ID: 22595021
    [Abstract] [Full Text] [Related]

  • 2. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
    Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V.
    PLoS One; 2013 Oct; 8(4):e60040. PubMed ID: 23573230
    [Abstract] [Full Text] [Related]

  • 3. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG.
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [Abstract] [Full Text] [Related]

  • 4. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.
    Hama AT, Germano P, Varghese MS, Cravatt BF, Milne GT, Pearson JP, Sagen J.
    PLoS One; 2014 Jan; 9(5):e96396. PubMed ID: 24788435
    [Abstract] [Full Text] [Related]

  • 5. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
    Karbarz MJ, Luo L, Chang L, Tham CS, Palmer JA, Wilson SJ, Wennerholm ML, Brown SM, Scott BP, Apodaca RL, Keith JM, Wu J, Breitenbucher JG, Chaplan SR, Webb M.
    Anesth Analg; 2009 Jan; 108(1):316-29. PubMed ID: 19095868
    [Abstract] [Full Text] [Related]

  • 6. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.
    Kwilasz AJ, Abdullah RA, Poklis JL, Lichtman AH, Negus SS.
    Behav Pharmacol; 2014 Apr; 25(2):119-29. PubMed ID: 24583930
    [Abstract] [Full Text] [Related]

  • 7. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures.
    Smaga I, Bystrowska B, Gawliński D, Pomierny B, Stankowicz P, Filip M.
    Neurotox Res; 2014 Aug; 26(2):190-206. PubMed ID: 24652522
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
    Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V.
    Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
    Jiang HX, Ke BW, Liu J, Ma G, Hai KR, Gong DY, Yang Z, Zhou C.
    Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of fatty acid amides in the carrageenan-induced paw edema model.
    Wise LE, Cannavacciulo R, Cravatt BF, Martin BF, Lichtman AH.
    Neuropharmacology; 2008 Jan; 54(1):181-8. PubMed ID: 17675189
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells.
    Li H, Wood JT, Whitten KM, Vadivel SK, Seng S, Makriyannis A, Avraham HK.
    Br J Pharmacol; 2013 Oct; 170(3):489-505. PubMed ID: 23347118
    [Abstract] [Full Text] [Related]

  • 12. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
    Spradley JM, Guindon J, Hohmann AG.
    Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
    [Abstract] [Full Text] [Related]

  • 13. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
    [Abstract] [Full Text] [Related]

  • 14. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents.
    Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P, Dargazanli G, Abouabdellah A, Cohen C, Bergis OE.
    Sci Rep; 2018 Feb 05; 8(1):2416. PubMed ID: 29403000
    [Abstract] [Full Text] [Related]

  • 15. The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice.
    Abohalaka R, Bozkurt TE, Nemutlu E, Onder SC, Sahin-Erdemli I.
    Pulm Pharmacol Ther; 2020 Jun 05; 62():101920. PubMed ID: 32416152
    [Abstract] [Full Text] [Related]

  • 16. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain.
    Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V.
    J Neurosci; 2006 Dec 20; 26(51):13318-27. PubMed ID: 17182782
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
    Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D.
    J Pharmacol Exp Ther; 2005 Apr 20; 313(1):352-8. PubMed ID: 15579492
    [Abstract] [Full Text] [Related]

  • 18. A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
    Malek N, Mrugala M, Makuch W, Kolosowska N, Przewlocka B, Binkowski M, Czaja M, Morera E, Di Marzo V, Starowicz K.
    Pain; 2015 May 20; 156(5):890-903. PubMed ID: 25719612
    [Abstract] [Full Text] [Related]

  • 19. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D.
    J Pharmacol Exp Ther; 2007 Jul 20; 322(1):236-42. PubMed ID: 17412883
    [Abstract] [Full Text] [Related]

  • 20. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
    Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF, Lichtman AH.
    Br J Pharmacol; 2012 Apr 20; 165(8):2485-96. PubMed ID: 21506952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.